Research

Research in the department of pharmacotherapy and translational research primarily focuses on understanding genetic and nongenetic factors that contribute to variability in drug response. The department has nearly two dozen faculty leading research initiatives at all three UF College of Pharmacy campuses in Gainesville, Jacksonville and Orlando.

Areas of Research

Precision Medicine / Implementation Science

Pharmacogenomics

Cardiovascular

Clinical Pharmacology / Drug Metabolism

Infectious Diseases

Oncology

Systems Pharmacology

Educational Research

Research Faculty

ASSOCIATE DEAN AND CLINICAL ASSOCIATE PROFESSOR

John Allen, Pharm.D.

* Antibiotic resistance
* Cancer survivorship
* Health disparities and Social determinants of health
* Health disparities and vulnerable populations
* Sepsis

Dr. John Allen

PROFESSOR AND THE DEBBIE DESANTIS TERM PROFESSOR IN THE UF COLLEGE OF PHARMACY

Larisa Cavallari, Pharm.D.

* Effectiveness of cardiovascular drugs
* Dose requirements of warfarin
* Opioid effectiveness and toxicity
* Drug metabolism enzyme activity and expression
* Outcomes with clinical implementation of genotype-guided therapy

Larisa Cavallari

RESEARCH ASSISTANT PROFESSOR

Joseph Collins, Ph.D.

* Epigenetic and genetic variation contributing to differences in pharmacogene expression
* Computational approaches to utilize public datasets for variant discovery and validation

Dr. Joseph Collins

ASSOCIATE PROFESSOR

Julio Duarte, Pharm.D., Ph.D.

* Effectiveness of cardiovascular drugs
* Genomics to identify novel drug targets for cardiopulmonary diseases
* Outcomes with clinical implementation of genotype-guided therapy

Dr. Julio Duarte

ASSOCIATE professor

Yang Gong, Ph.D.

* Effectiveness of cardiovascular drugs
* Cardiotoxic response to cancer treatments (Cardio-Oncology)
* Adverse drug response to antiresorptive drugs

Dr. Yan Gong

ASSOCIATE DEAN FOR RESEARCH AND GRADUATE EDUCATION; PROFESSOR AND THE FRANK A. DUCKWORTH EMINENT SCHOLAR CHAIR

Jatinder Lamba, Ph.D., M.Sc.

* Cancer treatment outcomes
* Toxicity to anti-leukemic agents
* CRISPR/cas9 mediated genetic perturbation screening in cancer
* Development of genomics guided immunotherapy for treatment of leukemia
* Systems biology approaches using multi-dimensional data to establish prognostic markers in cancer

Jatinder Lamba headshot

research assistant professor

Yinzhi Lang, Ph.D.

* Mechanistic assays to decode drug actions and resistance mechanisms
* UPLC-MS/MS for drug target site analysis and Quantitative and Systems Pharmacology (QSP) modeling
* Population pharmacokinetics/pharmacodynamics studies of anti-infective agents
* LC-MS/MS techniques for advanced glycomics and proteomics

Yinzhi Lang

assistant professor

Caitrin McDonough, Ph.D., M.S.

* Effectiveness of cardiovascular drugs
* Predisposition to adverse cardiovascular and cerebrovascular outcomes and high risk disease
* Development of multi-dimensional data models for cardiovascular disease identification and prediction
* Development of multi-dimensional data models for Alzheimer’s Disease and Related Dementias

Dr. Caitrin McDonough

clinical assistant professor

Khoa Nguyen, Pharm.D.

* Effectiveness of cardiovascular drugs
* Opioid effectiveness and toxicity
* Outcomes with clinical implementation of genotype-guided therapy

Khoa Nguyen

ASSOCIATE PROFESSOR

Luisel Ricks-Santi, Ph.D.

* Cancer treatment options
* Predisposition to aggressive breast and prostate cancer
* Genetic basis of cancer disparities
* Outcomes with clinical implementation of genotype-guided therapy

Dr. Luisel Ricks-Santi

Research Assistant Professor

Vivek Shastri, Ph.D.

* Identification, characterization, and validation of pharmacogenomic markers to predict response to therapy in acute myeloid leukemia, or AML, patients
* Developing and evaluating novel agents targeting CD33 isoforms to benefit AML patients not responding to currently available immunotherapy options

Vivek Shastri

RESEARCH ASSISTANT PROFESSOR

Marwa Tantawy, Ph.D.

* Cardiotoxic response in cancer treatment (Cardio-oncology)
* Pharmacogenomics and personalized medicine
* iPSC differentiation for mechanistic insights into cardiovascular complications

Marwa Tantawy

Clinical Associate Professor

Katie Vogel Anderson, Pharm.D.

* Evaluating student pharmacist success before and after the change in the PCAT requirement
* Patient education programs for pharmacogenomic testing

Katie Vogel Anderson

Established in 2001

Center for Pharmacogenomics and Precision Medicine

Research in the Center for Pharmacogenomics and Precision Medicine strives to identify genetic variations that affect drug response, with the goal of enabling safer and more effective drug therapy.

Drs. Cavallari and Duarte